ReviewUrologic oncology2014
The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research.
Review in Urologic oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed, 175 citations in OpenAlex.
- Feasibility of dietary folic acid reduction intervention for men on active surveillance for prostate cancer.Clinical nutrition ESPEN · 2021Trial
- Article
- Modular Nanotransporters Containing Anti-PSMA Nanobodies Are Able to Penetrate into the Nuclei of Prostate Cancer Cells.Doklady. Biochemistry and biophysics · 2026Article
- Can Tc-99m-PSMA SPECT/CT Be Used as Accessible Alternative for Diagnosis of Biochemically Recurrent Prostate Cancer? A Prospective Study.Diagnostics (Basel, Switzerland) · 2026Article
- Evaluating [Journal of market access & health policy · 2026Article
- Dutasteride treatment and its effect on standardized uptake values in prostate-specific membrane antigen-PET imaging: A pilot study.PloS one · 2026Article
- Novel PAP-targeted CAR-T therapy enhances antitumor efficacy through CoupledCAR approach.Journal for immunotherapy of cancer · 2025Article
- JHU-2545 preferentially shields salivary glands and kidneys during PSMA-targeted imaging.European journal of nuclear medicine and molecular imaging · 2025Article
- Liquid biopsies in cancer.Molecular biomedicine · 2025Review
- Review
- In-silico structural and functional analysis of nonsynonymous single nucleotide polymorphisms in humanIn silico pharmacology · 2025Article
- Synthesis and Preclinical Evaluation of a Bispecific PSMA-617/RM2 Heterodimer Targeting Prostate Cancer.ACS medicinal chemistry letters · 2024Article
- Description of FDG and Prostate-Specific Membrane Antigen PET/CT Findings in Korean Patients With Advanced Metastatic Castration-Resistant Prostate Cancer.Korean journal of radiology · 2024Article
- Review
- Nanoparticle-Mediated Drug Delivery Systems for Precision Targeting in Oncology.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Agreement between PSMA-RADS and E-PSMA systems in classifying [Frontiers in medicine · 2024Article
- Medicinal (Radio) Chemistry: Building Radiopharmaceuticals for the Future.Current medicinal chemistry · 2024Review
- PSMA PET imaging in the diagnosis and management of prostate cancer.Abdominal radiology (New York) · 2023Review
- Antitumor activity of AZD0754, a dnTGFβRII-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancer.The Journal of clinical investigation · 2023Article
- Population pharmacokinetic dosimetry model using imaging data to assess variability in pharmacokinetics ofCPT: pharmacometrics & systems pharmacology · 2023Article
32 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
objectiveDespite a multitude of detection and treatment advances in the past 2 decades, prostate cancer remains the second leading cause of deaths due to cancer among men in the United States. Technological evolution and expanding knowledge of tumor biomarkers have invigorated exploration in prostate cancer therapeutics. Prostate-specific membrane antigen (PSMA) was one of the first prostate cancer biomarkers successfully cloned. Since then, it has been characterized as the prototypical cell-surface marker for prostate cancer and has been the subject of intense clinical inquiry. In this article, we review the relevant research in PSMA on the 20th anniversary of its cloning. METHODS AND MATERIALS: A PubMed search using the keywords "prostate-specific membrane antigen" or "glutamate carboxypeptidase II" provided 1019 results. An additional 3 abstracts were included from scientific meetings. Articles were vetted by title and abstract with emphasis placed on those with clinically relevant findings.
resultsSixty articles were selected for inclusion. PSMA was discovered and cloned in 1993. Its structure and function were further delineated in the ensuing decade. Consensus sites of expression in normal physiology are prostate, kidney, nervous system, and small intestine. PSMA has been implicated in the neovasculature of several tumors including urothelial and renal cell carcinomas. In prostate cancer, expression of PSMA is directly related to the Gleason grade. PSMA has been tested both in imaging and therapeutics in a number of prostate cancer clinical trials. Several recent approaches to target PSMA include the use of small molecule inhibitors, PSMA-based immunotherapy, RNA aptamer conjugates, and PSMA-targeted prodrug therapy. Future study of PSMA in prostate cancer might focus on its intracellular functions and possible role in tumor neurogenesis.
conclusionsTwenty years from its discovery, PSMA represents a viable biomarker and treatment target in prostate cancer. Research to delineate its precise role in prostate carcinogenesis and within the therapeutic armamentarium for patients with prostate cancer remains encouraging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.